# Latency in Pulmonary Tuberculosis

> **NCT01154959** · PHASE3 · COMPLETED · sponsor: **Tuberculosis Research Centre, India** · enrollment: 120 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol

## Key facts

- **NCT ID:** NCT01154959
- **Lead sponsor:** Tuberculosis Research Centre, India
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2015-12
- **Final completion:** 2016-07
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154959, "Latency in Pulmonary Tuberculosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01154959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*